The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we approach type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 target agonists, which mimic the effects of a natural hormone that regulates blood sugar levels and appetite. Initially, developed for diabetic conditions, the… Read More